期刊文献+

膀胱癌患者外周血髓系来源的抑制细胞的比例及其临床意义 被引量:2

The prevalence of myeloid-derived suppressor cells in the peripheral blood of patients with bladder cancer
原文传递
导出
摘要 目的分析髓系来源的抑制细胞(myeloid-derived suppressor cells,MDSC)在膀胱癌患者外周血中的分布,初步探讨其临床意义。方法采用流式细胞术检测62例膀胱癌患者及20例健康人外周血中MDSC的比例,分析MDSC比例与临床病理特征和CD4+CD25high调节性T细胞(Treg)的关系。结果与正常对照(0.122±0.043)%相比,膀胱癌患者外周血中MDSC比例明显增加(0.679±0.438)%,二者差异有显著性(P<0.01);手术后,患者外周血中MDSC的比例明显下降,与术前比较有统计学意义(P<0.05);MDSC水平与膀胱癌肿瘤分期明显相关,而与肿瘤的分化程度和患者外周血Treg水平无显著相关(P>0.05)。结论膀胱癌患者外周血MDSC细胞水平明显升高,可能与肿瘤免疫功能低下及肿瘤发生发展密切相关。 Objective To investigate the prevalence of myeloid-derived suppressor cells(MDSCs)in the peripheral blood of patients with bladder carcinoma.Methods Flow cytometry was used to evaluate the prevalence of MDSCs in the peripheral blood of 62 patients with bladder carcinoma and 20 healthy people.The change of the frequency of MDSCs in the peripheral blood of 10 patients before and after operation was investigated.Furthermore,the relationship of peripheral blood MDSC level with pathological characteristics and the prevalence of CD4+CD25high regulatery T cells(Tregs) was determined statistically.Results Compared with normal control〔(0.122±0.043)%〕,the prevalence of MDSC in the peripheral blood of patients with bladder carcinoma was highly increased〔(0.679±0.438)%(P0.01)〕.After the operation,the frequency of MDSCs was decreased(P0.05).Circulating MDSCs was significantly increased in cancer patients of all stages compared with healthy volunteers.A significant correlation between circulating MDSCs and clinical tumor stage was also observed.However,no significant correlation between circulating MDSCs and the differentiation state of cancer,the prevalence of Tregs was observed.Conclusion The prevalence of MDSCs is increased in the peripheral blood of patients with bladder cancer.These cells may negatively regulate antitumor immune response of patients.
出处 《中国肿瘤临床与康复》 2010年第6期493-497,共5页 Chinese Journal of Clinical Oncology and Rehabilitation
关键词 膀胱肿瘤 髓系来源的抑制细胞 免疫逃逸 Bladder neoplasms Myeloid-derived suppressor cells Immune evasion
  • 相关文献

参考文献13

  • 1Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010[J]. CA Cancer J Clin, 2010,60:277-300.
  • 2Jacobs BL, Lee CT, Montie JE. Bladder cancer in 2010 : how far have we come[J]? CA Cancer J Clin, 2010, 60:244-272.
  • 3Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system[ J]. Nat Rev Immunol, 2009, 9:162-174.
  • 4Nagaraj S, Gabrilovich DI. Myeloid-derived suppressor cells in human cancer[ J]. Cancer J, 2010, 16:348-353.
  • 5Whiteside TL. Inhibiting the inhibitors: evaluating agents targe- ting cancer inununosuppression [ J ]. Expert Opin Biol Ther, 2010, 10:1019-1035.
  • 6Young MR, Newby M, Wepsic HT. Hematopoiesis and suppres- sor bone marrow cells in mice bearing large metastatic Lewis lung carcinoma tumors[ J]. Cancer Res, 1987, 47 : 100-105.
  • 7Sinha P, Clements VK, Bunt SK, et al. Cross-talk between mye- loid-derived suppressor cells and macrophages subverts tumor im- munity toward a type 2 response[J]. J Immunol, 2007, 179: 977-983.
  • 8Murdoch C, Muthana M, Coffelt SB, et al. The role of myeloid ceils in the promotion of tumour angiogenesis[ J]. Nat Rev Canc- er, 2008, 8:618-631.
  • 9Kusmartsev S, Gabrilovich DI. Inhibition of myeloid cell differ- entiation in cancer: the role of reactive oxygen species [ J]. J Leukoc Biol, 2003, 74 : 186-196.
  • 10Ochoa AC, Zea AH, Hernandez C, et al. Arginase, prostaglan- dins, and myeloid-derived suppressor cells in renal cell carcino- ma[J]. Clin Cancer Res, 2007, 13:721s-726s.

同被引文献15

  • 1Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system[J]. Nat Rev immunol,2009,9(3) :162-174.
  • 2Nagaraj S, Gabn'lovich DI. Myeloid-derived suppressor cells in human cancer [J]. Cancer, 2010, 16(4) :348-353.
  • 3Yang R. CD80in immune suppression by mouse ovarian carcinoma-as- sociated Gr-1 + CDllb + myeloidcells [ J. Cancer Res, 2006,66 (3) :6807-6815.
  • 4Pan PY, Wang GX, Yin B, et al. Reversion of immune to tolerance in advanced malignancy:modulation of myeloid-derived suppressor cell development by blockade of stem-cell factor function [ J 1. Blood, 2008, 111 ( 1 ) :219-228.
  • 5Serafini P, Carbley R, Noonan KA, et al. High-dose granulocyte- macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells[J]. Cancer Res, 2004, 64(17) :6337-6343.
  • 6Bunt SK, Yang L, Sinha P, et al. Reduced inflammation in the tumor microenvironment delays the accumulation of myeloid-derived suppressor cells and limits tumor progression[ J 1. Cancer Res, 2007, 67(20) :10019-10026.
  • 7Sinha P, Okoro C, Foell D, et al. Proinflammatory S100 proteins reg- ulate the accumulation of myeloid-derived suppressor cells[ J. J Im- munol, 2008, 181(7) :4666-4675.
  • 8Nefedova Y, Nagaraj S, Rosenbaner A, et al. Regulation of dendritic cell differentiation and antitumor immune response in eaneer by phar- macologic-selective inhibition of the janus-activated kinase 2/sigual transducers and activators of transcription 3 pathway[ J]. Cancer Res, 2005, 65 ( 20 ) : 9525-9535.
  • 9Nefedova Y, Huang M, Kusmartsev S, et al. Hyperactivation of STAT3 is involved in abnormal differentiation of dendritic cells in cancer[J]. J Immuol, 2004, 172(1 ) :464-474.
  • 10Enocsson H, Sjtwall C, Skogh T, et al. Interferon-alpha mediates suppression of C-reactive protein: explanation for muted-C-reactive protein response in lupus flares [ J ] ? Arthritis Rheum, 2009, 60 (12) :3755-3760.

引证文献2

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部